New drug versus chemotherapy for advanced epithelioid mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (called a TEAD inhibitor) against two standard chemotherapy drugs (gemcitabine and vinorelbine) for people with advanced epithelioid mesothelioma who have already had chemotherapy and immunotherapy. The study aims to see if the new drug works better than the standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of advanced epithelioid pleural mesothelioma (a cancer of the lung lining).
- You must have already tried platinum-based chemotherapy and immunotherapy for your mesothelioma; these can be given together or one after the other.
- Your cancer must be measurable on a scan (like CT or MRI), and you should be in relatively good health (able to do light activities).
- You cannot have active brain metastases, uncontrolled infections (like HIV, hepatitis B or C), or serious heart problems.
- If you have received one of the study comparison drugs (gemcitabine or vinorelbine) before, you can still join, but you won't be given that same drug again.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests VT3989 in people with specific advanced (metastatic or unresectable) cancers. It may help shrink tumors or slow cancer growth in patients who fit the genetic or diagnosis-specific requirements.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps people with malignant mesothelioma live longer and feel better. It's for patients who can't have surgery or radiation, and it may be an option if you haven't had treatment before or have had limited prior treatment.
This trial tests a new drug called BMS-986504 in people whose mesothelioma has come back after treatment and whose tumors lack a protein called MTAP. The drug may help by blocking a specific pathway that these cancer cells need to grow.
This trial tests whether adding more chemotherapy directly into the belly after surgery can improve outcomes for people with a specific type of peritoneal mesothelioma. It may help reduce the chance of the cancer coming back.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
Hear when a new Pleural Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.